Chlorogenic acid modulates gut microbiota and metabolites to alleviate intrahepatic cholestasis of pregnancy: Insights from 16S rRNA sequencing and metabolomics. [PDF]
Ma D +8 more
europepmc +1 more source
Retrospective evaluation of high-dose-rate brachytherapy multicriteria planning using physical dose versus radiobiological criteria for prostate cancer. [PDF]
Iorio-Duval C +3 more
europepmc +1 more source
Accumulated dose on daily iCBCT for rectal cancer: Effects of inter-fraction bowel cavity motion volume. [PDF]
Zeng H +6 more
europepmc +1 more source
A marginal structural model for normal tissue complication probability. [PDF]
Tang TS +4 more
europepmc +1 more source
External validation and updating of NTCP models for radiation pneumonitis: QUANTEC, Appelt, and a local simplified model. [PDF]
Chen Z +8 more
europepmc +1 more source
From standard to stratified: Modeling NTCP and EAR to personalize daily MV-CBCT in radiotherapy. [PDF]
Tai DT +9 more
europepmc +1 more source
Related searches:
Hepatitis B virus (HBV) infection is mediated by a specific interaction with sodium taurocholate-cotransporting polypeptide (NTCP), a viral entry receptor. Although the virus-receptor interactions are believed to trigger viral internalization into host cells, the exact molecular mechanisms of HBV internalization are not understood.
Samyong Park +2 more
exaly +3 more sources
NTCP opens the door for hepatitis B virus infection
Antiviral Research, 2015A liver bile acids transporter, sodium taurocholate cotransporting polypeptide (NTCP, encoded by SLC10A1) was recently identified as a functional receptor for hepatitis B virus (HBV) and its satellite hepatitis D virus (HDV). NTCP-complemented human hepatoma HepG2 cells (HepG2-NTCP) were shown to support infection of HBV and HDV in vitro, providing a ...
Huan Yan, Jianhua Sui, Wenhui Li
exaly +3 more sources
Clinical effects of NTCP‐inhibitor myrcludex B
Journal of Viral Hepatitis, 2021AbstractWith extensive research on the pathogenesis and treatment of hepatitis B virus (HBV) and hepatitis D virus (HDV) infections, the current treatment of interferon and nucleoside or nucleotide analogues provides reasonable control of viral replication in chronic hepatitis B (CHB).
Dongliang Cheng +3 more
openaire +2 more sources
NTCP: a pharmacological target for multiple liver conditions
Gut, 2021Despite major therapeutic advances to treat patients with chronic liver diseases, one target remains elusive in hepatology and this is the most important one: liver fibrosis. We can cure patients from chronic hepatitis C; we can vaccinate against hepatitis B virus and control chronic hepatitis B; we have new drugs to treat cholestatic liver diseases ...
Jordi Gracia-Sancho +1 more
openaire +2 more sources

